CNBX Pharmaceuticals is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patients specific profile. By developing tools to assess effectiveness on a personalized basis, Cannabics seeks to make cannabinoids part of the future of cancer therapy.
CNBX Pharmaceuticals operates In Israel as G.R.I.N Ultra Ltd where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.
Cumulative Funding Raised Over Time ($)
Employees Over Time
CNBX Pharmaceuticals Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Oct 13, 2022
www.prnewswire.com
CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel
#Customers
Mar 28, 2022
www.prnewswire.com
Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
#Management Changes
Jun 13, 2020
www.prnewswire.com
Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis
#Customers #Expand
May 10, 2020
www.prnewswire.com
Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma
#Investment, Expand
Dec 11, 2018
Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization